Cargando…

Low-dose Erythropoietin reduces risk of heart failure induced by anti-cancer therapy

Detalles Bibliográficos
Autores principales:	Hoch, Melanie, Hilfiker-Kleiner, Denise
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2011
Materias:	Editorial Comments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3259998/ https://www.ncbi.nlm.nih.gov/pubmed/22084151

Ejemplares similares

Neuraminidase-1 promotes heart failure after ischemia/reperfusion injury by affecting cardiomyocytes and invading monocytes/macrophages
por: Heimerl, Maren, et al.
Publicado: (2020)

Cell Therapy for Heart Failure With Preserved Ejection Fraction
por: Borlaug, Barry A., et al.
Publicado: (2016)

Breastfeeding in Patients With Heart Failure: Lack of Evidence and Consensus
por: Koenig, Tobias, et al.
Publicado: (2019)

Common genetic predisposition for heart failure and cancer
por: Pfeffer, Tobias J., et al.
Publicado: (2020)

Fine Tuning Adenylyl Cyclase as a (Gene) Therapy for Heart Failure
por: Port, J. David, et al.
Publicado: (2016)

Chemotherapy-Free Targeted Anti-BCR-ABL+ Acute Lymphoblastic Leukemia Therapy May Benefit the Heart
por: Kirchhoff, Hanna, et al.
Publicado: (2022)

Hydrogen Sulfide Therapy Promotes Beneficial Systemic Effects in Experimental Heart Failure
por: Nabeebaccus, Adam A., et al.
Publicado: (2018)

Empagliflozin and the Prevention of Heart Failure: Will Reverse Translation Lead to New Paradigms for the Treatment of Heart Failure?
por: Mann, Douglas L., et al.
Publicado: (2017)

Innovation in Diuretic Therapy: The Missing Ingredient for Treating Worsening Heart Failure Outside the Hospital?
por: Greene, Stephen J., et al.
Publicado: (2018)

Heart rate in heart failure with mid-range ejection fraction
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

The Role of Macrophages in Nonischemic Heart Failure
por: Chen, Bijun, et al.
Publicado: (2018)

A Growth Tonic for Heart Failure?
por: Bishopric, Nanette H.
Publicado: (2016)

Kardiologie: Grenzen überwinden, neue Welten entdecken
por: Hilfiker-Kleiner, Denise, et al.
Publicado: (2021)

STAT3 regulation of and by microRNAs in development and disease
por: Haghikia, Arash, et al.
Publicado: (2012)

Cardiac BIN1 Replacement Therapy Ameliorates Inotropy and Lusitropy in Heart Failure by Regulating Calcium Handling
por: Gambardella, Jessica, et al.
Publicado: (2020)

Reconsidering Renal Sympathetic Denervation for Heart Failure
por: Tang, W.H. Wilson, et al.
Publicado: (2017)

Brain-derived neurotrophic factor in heart failure
por: Yılmaz, Mehmet Birhan
Publicado: (2019)

Oxytocin: A New Therapeutic for Heart Failure?
por: Habecker, Beth A.
Publicado: (2020)

Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy
por: Nonhoff, Justus, et al.
Publicado: (2017)

Metabolic Coupling as a Therapeutic Strategy for Heart Failure
por: Young, Martin E.
Publicado: (2019)

Data on left ventricular expression of STAT3 and AKT in transgenic mouse models with B16F10 melanoma
por: Pietzsch, Stefan, et al.
Publicado: (2019)

Abnormal heart rate recovery in patients with heart failure: an important target for exercise training treatment
por: Dimopoulos, Stavros
Publicado: (2015)

Beyond lipid lowering: pleiotropic effects of statins in heart failure
por: Swenne, C. A.
Publicado: (2013)

Cardiometabolic Heart Failure and HFpEF: Still Chasing Unicorns
por: Sharp, Thomas E., et al.
Publicado: (2019)

Targeting Mitochondrial Function in Heart Failure: Makes Sense But Will it Work?
por: Khan, Muhammad Shahzeb, et al.
Publicado: (2019)

Modulation of Glucagon Signaling: A Metabolic Approach for Heart Failure?
por: Pocai, Alessandro
Publicado: (2019)

Promoting Health Equity in Heart Failure Amid a Pandemic
por: DeFilippis, Ersilia M., et al.
Publicado: (2021)

Unraveling the Mechanisms by Which Calpain Inhibition Prevents Heart Failure Development
por: Wehrens, Xander H.T.
Publicado: (2018)

Does nitric oxide mediate the effects of ivabradine in patients with heart failure?
por: Mączewski, Michał
Publicado: (2018)

Role of ischemia-modified albumin in patients with acute decompensated heart failure
por: Pan, Defeng, et al.
Publicado: (2016)

Heart failure guidelines implementation: Lifting barriers using registries and networks
por: Keramida, Kalliopi, et al.
Publicado: (2020)

Understanding Heart Failure With Preserved Ejection Fraction in a Diabetic Way
por: Li, Haobo, et al.
Publicado: (2021)

Clinical evaluation of heart failure patients: what good are biomarkers bringing us?
por: de Boer, R. A.
Publicado: (2014)

To implant or not to implant?: That is the unsolved question concerning heart failure patients with non-LBBB
por: Zarse, M., et al.
Publicado: (2015)

Follistatin-Like 1: Growing Evidence for Its Beneficial Role in Heart Failure
por: Wollert, Kai C.
Publicado: (2016)

Heart Failure With Preserved Ejection Fraction in Women: New Clues to Causes and Treatment
por: Barton, Matthias, et al.
Publicado: (2020)

Low-dose CT angiography: sufficient contrast for vessel imaging?
por: van der Wall, E. E., et al.
Publicado: (2009)

Tissue transglutaminase in the pathogenesis of heart failure
por: Shinde, Arti V., et al.
Publicado: (2017)

Left ventricular assist device for end-stage heart failure: results of the first LVAD destination program in the Netherlands: Towards LVAD destination therapy in the Netherlands?
por: Manintveld, O. C.
Publicado: (2014)

Pulmonary hypertension in the changing landscape of congenital heart disease: Global differences and a possible driver of end-stage heart failure
por: Van De Bruaene, A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_7m7n2pb7je4e8sp240kjrbae7n